Neuronetics, Inc. Integrates TrakStar With AdvancedMD, Inc. To Deliver TMS Care Across Clinical, Operational, And Billing Workflows

Neuronetics, Inc. integrated its TrakStar platform with AdvancedMD, Inc.'s EHR system. This is the first TMS system to integrate with an EHR/EMR. The collaboration aims to streamline clinical, operational, and billing workflows. The integration will be available to NeuroStar providers using AdvancedMD in Q4. Early adopter CSIP reported reduced duplicate work and improved operations.

Original reporting
Published Sep 8, 2026, 2:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$STIM
Neutral
medium confidence
Mentioned
$STIM
Relevance
4/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$STIMNeutralLow
01

Why it matters

The integration aims to streamline clinical and billing workflows, reducing administrative burden for providers.

02

Market read

A modest product partnership that could improve operational efficiency for NeuroStar users, with limited immediate market impact.

03

What to watch

Adoption speed depends on provider willingness to switch systems; competitive EHR solutions may limit impact.

Relevance 4/10Novelty 4/10Timing: integration available starting Q4 2026

Background

Neuronetics (STIM) provides the NeuroStar TMS system for depression treatment. AdvancedMD offers cloud‑based EHR and practice‑management software.

Company-level read

Ticker impact

$STIMNeutralMedium confidence
Context

Neuronetics announced its TrakStar platform will integrate with AdvancedMD's EHR system, a first for NeuroStar TMS devices.

Expected impact

Modest upside if integration drives higher device utilization; no immediate catalyst.

Evidence & confidence

Integration is a positive development but lacks quantifiable financial impact or scale.

Market effects

May encourage other TMS manufacturers to pursue EHR integrations, modestly strengthening the neurostimulation sector.

U.S. neurotechnology market sees incremental service improvement; limited broader regional effect.

Limited global relevance; primarily affects U.S. providers using NeuroStar.

Counterpoint

Integration could be a distraction; without clear revenue upside, investors may remain indifferent.

Key entities

  • Neuronetics, Inc.

    U.S. listed provider of the NeuroStar TMS system.

  • AdvancedMD, Inc.

    Private cloud‑based EHR and practice‑management platform.

Related articles

$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.